DAVID ZACCARDELLI
CIK 1627642 · President and CEO · last filed 2026-07-09
DAVID ZACCARDELLI is a President and CEO who has filed 111 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for VOR, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$45.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $807.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$807.4K
7
111
-$45.62M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | — | $20.00 | — | $0 | 1 | 2026-07-09 |
| SABSW | Director | — | $0.01 | — | $0 | 1 | 2026-01-07 |
| Verona Pharma plc (VRNA) Delisted | President and CEO | 3,285,280 | $106.91 | $351.23M | -$35.28M | 43 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | President & CEO | 0 | — | — | -$253.1K | 4 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | 9,300 | — | — | $200.0K | 3 | 2019-06-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Acting Chief Executive Officer | — | — | — | $0 | 2 | 2016-12-13 |
| UTHR | EVP & Chief Operating Officer | 1,542 | $523.63 | $807.4K | -$10.29M | 50 | 2016-05-16 |
Recent Filings
111 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-09 | VOR | Grant (A) | — | $0 | EDGAR |
| 2026-01-07 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2025-10-08 | Verona Pharma plc (VRNA) Delisted | Mixed | −12,176,144 | $0 | EDGAR |
| 2025-09-03 | Verona Pharma plc (VRNA) Delisted | Gift (G) | −1,200,000 | $0 | EDGAR |
| 2025-08-05 | Verona Pharma plc (VRNA) Delisted | Mixed | +46,784 | -$2.75M | EDGAR |
| 2025-07-09 | Verona Pharma plc (VRNA) Delisted | Mixed | +139,192 | -$1.03M | EDGAR |
| 2025-06-13 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −400,000 | -$4.56M | EDGAR |
| 2025-06-11 | — | Notice (144) | −50,000 | -$4.34M | EDGAR |
| 2025-05-29 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −400,000 | -$3.73M | EDGAR |
| 2025-05-27 | — | Notice (144) | −50,000 | -$3.75M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.